The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 18, 2025
Filed:
Sep. 04, 2019
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Nantes Universite, Nantes, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Institut National DE Recherche Pour L'agriculture, L'alimentation ET L'environnement, Paris, FR;
Chu Nantes, Nantes, FR;
Bertrand Cariou, Nantes, FR;
Antoine Magnan, Nantes, FR;
Grégory Bouchaud, Nantes, FR;
Cédric Le May, Nantes, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITE DE NANTES, Nantes, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVRIONMENT, Paris, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes, FR;
Abstract
The present invention relates to the allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determined its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9−/−) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.